title: C-MET overexpression and amplification in gliomas.
abstract: We investigated c-Met overexpression and MET gene amplification in gliomas to determine their incidence and prognostic significance. c-Met immunohistochemistry and MET gene fluorescence in situ hybridization were carried out on tissue microarrays from 250 patients with gliomas (137 grade IV GBMs and 113 grade II and III diffuse gliomas). Clinicopathological features of these cases were reviewed. c-Met overexpression and MET gene amplification were detected in 13.1% and 5.1% of the GBMs, respectively. All the MET-amplified cases showed c-Met overexpression, but MET amplification was not always concordant with c-Met overexpression. None of grade II and III gliomas demonstrated c-Met overexpression or MET gene amplification. Mean survival of the GBM patients with MET amplification was not significantly different from patients without MET amplification (P=0.155). However, GBM patients with c-Met overexpression survived longer than patients without c-Met overexpression (P=0.035). Although MET amplification was not related to poor GBM prognosis, it is partially associated with the aggressiveness of gliomas, as MET amplification was found only in grade IV, not in grade II and III gliomas. We suggest that MET inhibitor therapy may be beneficial in about 5% GBMs, which was the incidence of MET gene amplification found in the patients included in this study.
authors.affiliation: Department of Pathology, Seoul National University Hospital Seoul, Republic of Korea.
authors.forename: Yoonjin
authors.initials: Y
authors.lastname: Kwak
authors.affiliation: Department of Pathology, Seoul National University Hospital Seoul, Republic of Korea.
authors.forename: Seong-Ik
authors.initials: SI
authors.lastname: Kim
authors.affiliation: Department of Neurosurgery, Seoul National University Hospital Seoul, Republic of Korea.
authors.forename: Chul-Kee
authors.initials: CK
authors.lastname: Park
authors.affiliation: Department of Neurosurgery, Seoul National University Hospital Seoul, Republic of Korea.
authors.forename: Sun Ha
authors.initials: SH
authors.lastname: Paek
authors.affiliation: Department of Neurology, Seoul National University Hospital Seoul, Republic of Korea.
authors.forename: Soon-Tae
authors.initials: ST
authors.lastname: Lee
authors.affiliation: Department of Pathology, Seoul National University HospitalSeoul, Republic of Korea; Institute of Neuroscience, Seoul National University, College of MedicineSeoul, Republic of Korea.
authors.forename: Sung-Hye
authors.initials: SH
authors.lastname: Park
mesh_terms: D000328:Adult; D000368:Aged; D001932:Brain Neoplasms / Q000235:genetics* / Q000401:mortality / Q000473:pathology*; D005260:Female; D005784:Gene Amplification; D005910:Glioma / Q000235:genetics* / Q000401:mortality / Q000473:pathology*; D006801:Humans; D007150:Immunohistochemistry; D017404:In Situ Hybridization, Fluorescence; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D019859:Proto-Oncogene Proteins c-met / Q000096:biosynthesis* / Q000235:genetics; D046888:Tissue Array Analysis; D015854:Up-Regulation
chemical_list: D019859:Proto-Oncogene Proteins c-met
keywords: Brain tumor; FISH; c-Met; glioblastoma; immunohistochemistry; target therapy
references.citation: Oncogene. 2003 May 8;22(18):2812-22
references.pmid: 12743604
references.citation: Brain Pathol. 2013 Jan;23(1):13-8
references.pmid: 22672415
references.citation: J Korean Neurosurg Soc. 2010 Aug;48(2):145-52
references.pmid: 20856664
references.citation: Infect Agent Cancer. 2013 Apr 08;8(1):13
references.pmid: 23566349
references.citation: Int J Dev Neurosci. 1999 Aug-Oct;17(5-6):517-30
references.pmid: 10571413
references.citation: Int J Cancer. 2006 Feb 1;118(3):583-92
references.pmid: 16106403
references.citation: N Engl J Med. 2005 Nov 10;353(19):2012-24
references.pmid: 16282176
references.citation: J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89
references.pmid: 15977639
references.citation: Proc Natl Acad Sci U S A. 2012 Jan 10;109(2):570-5
references.pmid: 22203985
references.citation: Evid Based Complement Alternat Med. 2013;2013:243859
references.pmid: 23533466
references.citation: Clin Cancer Res. 2005 Jun 15;11(12):4479-86
references.pmid: 15958633
references.citation: Cancer Res. 2012 Jul 1;72(13):3302-11
references.pmid: 22552292
references.citation: Neuropathology. 2007 Feb;27(1):10-20
references.pmid: 17319279
references.citation: Histopathology. 2008 May;52(6):738-46
references.pmid: 18397279
references.citation: Oncogene. 2004 Dec 9;23(57):9173-82
references.pmid: 15516982
references.citation: J Neurol Sci. 2010 Jul 15;294(1-2):112-8
references.pmid: 20441994
references.citation: Oncogene. 2005 May 26;24(23):3697-707
references.pmid: 15782129
references.citation: Cancer. 2009 Jan 1;115(1):140-8
references.pmid: 18973197